Strong double-digit revenue growth for Ipsen in 3rd-qtr

24 October 2019

Shares of French specialty pharma group Ipsen (Euronext: IPN) gained 1.8% to 93.45 euros by midday trading after it that group sales for the third-quarter of 2019, at 644.7 million euros ($716.9 million) saw growth of +16.0% as reported and +14.5% at constant exchange rates.

Revenue was driven by Specialty Care sales growth of 16.5%, reflecting strong double-digit momentum of Somatuline (lanreotide) and the continued growth from Cabometyx (cabozantinib) and Decapeptyl (triptorelin).

Full-year 2019 guidance was confirmed with group sales growth of greater than +14.0% at constant currency and consolidation scope and core operating margin at around 30.0% of net sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK